17:55:50 EST Tue 17 Nov 2026
Enter Symbol
or Name
USA
CA



Login ID:
Password:
Save

Q:MBRX - MOLECULIN BIOTECH INC - https://moleculin.com
Sym-XBid - AskLastChg%ChVol$Vol#TrOpen-Hi-LoYear Hi-LoLast TrNewsDelay
MBRX - Q0.15.77·9.940.16.83-0.31-4.312.0714597.50  7.50  6.81228.50  3.22816:10:05Nov 1615 min RT 2¢

Recent Trades - Last 10 of 459
Time ETExPriceChangeVolume
16:10:05Q6.98-0.161
16:10:04Q6.98-0.161
16:10:04Q6.98-0.161
16:04:01Q6.98-0.161
16:04:01Q6.98-0.161
16:04:00Q6.98-0.161
16:04:00Q6.98-0.161
16:02:35Q7.11-0.0320
16:00:11Q6.98-0.161
16:00:11Q6.98-0.161

Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS

Recent Bulletins
Date ETSymbolTypeHeadline
2026-11-16 07:30U:MBRXNews ReleaseMoleculin Biotech Reports Third Quarter 2026 Financial Results as Pivotal MIRACLE Trial Advances Toward Key Q1 2027 Data Readout
2026-11-12 08:37U:MBRXNews ReleaseMoleculin Secures Australian Patent for Annamycin Formulation Technology
2026-11-10 14:45U:MBRXNews ReleasePreclinical Data Show Annamycin Makes Pancreatic Cancer Responsive to Checkpoint Inhibitors, Opening a Combination Path with Immunotherapies
2026-11-04 11:00U:MBRXNews ReleaseMoleculin Announces Acceptance of Annamycin Data for Presentation at the 2026 American Society of Hematology (ASH) Annual Meeting
2026-10-30 08:40U:MBRXNews ReleaseMoleculin Completes Dosing Patients in Part A of Pivotal MIRACLE Trial; Comprehensive Data Readout on Track for Q1 2027
2026-10-20 08:12U:MBRXNews ReleaseMoleculin Releases Next CEO Corner Segment Highlighting Recent Progress in Annamycin MIRACLE Trial
2026-10-16 09:20U:MBRXNews ReleaseMoleculin Announces Reverse Stock Split
2026-10-07 08:45U:MBRXNews ReleaseMoleculin Biotech to Participate in Advances in Oncology Panel at the 2026 Maxim Growth Summit
2026-09-29 08:45U:MBRXNews ReleaseMoleculin Biotech Completes Enrollment in Part A of Phase 2/3 R/R AML MIRACLE Trial, Keeping Program on Track for Q1 2027 Data Readout
2026-09-28 07:00U:MBRXNews ReleaseMoleculin Announces Publication of Peer-Reviewed Cardiac Safety Analysis of Annamycin in Frontiers in Cardiovascular Medicine
2026-09-25 13:05U:MBRXNews ReleaseAnnamycin Turns "Cold" Pancreatic Tumors "Hot" in New Preclinical Data Presented at AACR
2026-09-23 08:25U:MBRXNews ReleaseMoleculin Biotech Secures Mexican Patent Protecting Lung-Targeted Liposomal Annamycin Through 2040
2026-09-14 08:35U:MBRXNews ReleaseMoleculin to Showcase New Annamycin Data at AACR Conference on Pancreatic Cancer and Two European Scientific Meetings
2026-09-11 08:30U:MBRXNews ReleaseMoleculin Presentation from H.C. Wainwright Conference Now Available On-Demand
2026-08-27 09:01U:MBRXNews ReleaseMoleculin CEO, Walter Klemp, Participates in the Virtual Investor "Why Now" On-Demand Conference
2026-08-14 08:30U:MBRXNews ReleaseMoleculin Biotech Reports Second Quarter 2026 Financial Results and Highlights Continued Advancement of Pivotal MIRACLE Trial
2026-07-31 10:12U:MBRXNews ReleaseMoleculin Announces Pricing of $9.3 Million Public Offering
2026-07-31 08:10U:MBRXNews ReleaseMoleculin's MIRACLE R/R AML Trial Reports Positive Interim Data with 37% Blinded CRc in Venetoclax-Failed Patients
2026-07-06 08:33U:MBRXNews ReleaseMoleculin CEO, Walter Klemp, Highlights Positive Preliminary MIRACLE Trial Results in Virtual Investor "What This Means" Segment
2026-06-30 08:30U:MBRXNews ReleaseMoleculin Reports Positive Phase 2/3 MIRACLE Interim Results, With Annamycin Complete Remission Rates 3-fold Greater than Control